35
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Emerging Omicron sub-variants are causing global concerns, and their immune evasion should be monitored continuously. We previously evaluated the escape of Omicron BA.1, BA.1.1, BA.2 and BA.3 from an atlas of 50 monoclonal antibodies (mAbs), covering seven epitope classes of the SARS-CoV-2 receptor-binding domain (RBD). Here, we update the atlas of totally 77 mAbs against emerging sub-variants including BQ.1.1 and XBB and find that BA.4/5, BQ.1.1 and XBB display further evasion. Besides, investigation into the correlation of binding and neutralization of mAbs reveals the important role of antigenic conformation in mAb functioning. Moreover, the complex structures of BA.2 RBD/BD-604/S304 and BA.4/5 RBD/BD-604/S304/S309 further elucidate the molecular mechanism of antibody evasion by these sub-variants. By focusing on the identified broadly potent mAbs, we find a general hotspot epitope on the RBD, which could guide the design of vaccines and calls for new broad-spectrum countermeasures against COVID-19.

          Graphical abstract

          Abstract

          Immune evasion of SARS-CoV-2 variants needs to be monitored continuously. He et al. assess the efficacy of 77 neutralizing mAbs against recently emerging Omicron sub-variants including BQ.1.1 and XBB. They reveal the binding-neutralization correlation of mAbs and point out a hotspot epitope targeting by broadly neutralizing antibodies.

          Related collections

          Author and article information

          Journal
          Cell Rep Med
          Cell Rep Med
          Cell Reports Medicine
          The Author(s).
          2666-3791
          21 March 2023
          21 March 2023
          : 100991
          Affiliations
          [1 ]Department of Microbiology, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310058, China
          [2 ]CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
          [3 ]University of the Chinese Academy of Sciences, Beijing 100049, China
          [4 ]Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China
          [5 ]School of Life Science, University of Science and Technology of China, Hefei, Anhui Province 230026, China
          [6 ]Shanxi Academy of Advanced Research and Innovation, Taiyuan, Shanxi Province 030032, China
          [7 ]Chinese Center for Disease Control and Prevention, Beijing 102206, China
          Author notes
          []Corresponding author (J.Q.), (G.F.G.) and (Q.W.)
          [8]

          Lead Contact

          [#]

          These authors contributed equally.

          Article
          S2666-3791(23)00097-6 100991
          10.1016/j.xcrm.2023.100991
          10027947
          37019110
          08907c81-0a04-435f-8cfb-d1de8bcd3d3f
          © 2023 The Author(s)

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 30 July 2022
          : 3 February 2023
          : 14 March 2023
          Categories
          Article

          sars-cov-2,omicron ba.2.12.1,ba.2.13,ba.2.75,ba.4,ba.5,bq.1.1,xbb,human neutralizing antibodies,immune escape

          Comments

          Comment on this article